An economic evaluation of donepezil in mild to moderate Alzheimer's disease: results of a 1-year, double-blind, randomized trial.

A, Wimo; B, Winblad; K, Engedal; H, Soininen; F, Verhey; G, Waldemar; AL, Wetterholm; V, Mastey; A, Haglund; R, Zhang; R, Miceli; W, Chin; P, Subbiah

doi:10.1159/000066669

Public

An economic evaluation of donepezil in mild to moderate Alzheimer's disease: results of a 1-year, double-blind, randomized trial.

Shared by NobleBlocks on Jan 1, 2003 • 12:00 AM UTC

Authors:

Wimo A

Winblad B

Engedal K

Abstract

The costs and consequences of donepezil versus placebo treatment in patients with mild to moderate Alzheimer's disease (AD) were evaluated as part of a 1-year prospective, double-blind, randomized, multinational clinical trial. Patients received either donepezil (n = 142; 5 mg/day for 28 days follow...

Discussions